CliffBio
biologic

Jubereq

denosumab-desu

Loss of exclusivity—loss of exclusivity
CompanyAccord Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameJubereq
Active ingredientdenosumab-desu
Strength120MG/1.7ML (70MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2025
Marketing statusRx

More from Accord Biopharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.